A J Donne1, L Hampson, J J Homer, I N Hampson. 1. Department of Otolaryngology, Alder Hey Children's NHS Foundation Trust, Eaton Road, Liverpool, L12 2AP, United Kingdom. ajdonne@doctors.org.uk
Abstract
OBJECTIVE: Human Papillomavirus (HPV) 6 and 11 are the aetiological agents responsible for Recurrent Respiratory Papillomatosis (RRP). There is general consensus that HPV11 results in more aggressive disease compared to HPV6. METHOD: Pubmed was searched using the terms respiratory papillomatosis, HPV 6 and HPV11. Comparisons were made in the outcomes of HPV6 versus HPV11 positive RRP disease. RESULTS: There are numerous sub-types or variants of both HPV6 and HPV11. These sub-types have different activities at least in-vitro. The numbers of different HPV types within RRP tissue may be more extensive than initially appeared. This depends specifically upon the HPV types tested for. CONCLUSION: The clinical differences between HPV6 and HPV11 disease may not be accurately predictable as these viruses exist in numerous sub-types. Also, RRP tissue may contain more than one subtype or even be co-infected with other viruses that may influence outcome. In-vitro studies upon cell lines are a reasonable starting point for evaluation of these differences. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
OBJECTIVE:Human Papillomavirus (HPV) 6 and 11 are the aetiological agents responsible for Recurrent Respiratory Papillomatosis (RRP). There is general consensus that HPV11 results in more aggressive disease compared to HPV6. METHOD: Pubmed was searched using the terms respiratory papillomatosis, HPV 6 and HPV11. Comparisons were made in the outcomes of HPV6 versus HPV11 positive RRP disease. RESULTS: There are numerous sub-types or variants of both HPV6 and HPV11. These sub-types have different activities at least in-vitro. The numbers of different HPV types within RRP tissue may be more extensive than initially appeared. This depends specifically upon the HPV types tested for. CONCLUSION: The clinical differences between HPV6 and HPV11 disease may not be accurately predictable as these viruses exist in numerous sub-types. Also, RRP tissue may contain more than one subtype or even be co-infected with other viruses that may influence outcome. In-vitro studies upon cell lines are a reasonable starting point for evaluation of these differences. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors: Eduardo Lazcano-Ponce; Staci L Sudenga; B Nelson Torres; Mark Stoler; Leith León-Maldonado; Betania Allen-Leigh; Héctor Posso; Manuel Quiterio; María Del Pilar Hernández-Nevarez; Jorge Salmerón; Anna R Giuliano Journal: Salud Publica Mex Date: 2018 Nov-Dec
Authors: Hang Yuan; Scott Myers; Jingang Wang; Dan Zhou; Jennifer A Woo; Bhaskar Kallakury; Andrew Ju; Michael Bazylewicz; Yvonne M Carter; Christopher Albanese; Nazaneen Grant; Aziza Shad; Anatoly Dritschilo; Xuefeng Liu; Richard Schlegel Journal: N Engl J Med Date: 2012-09-27 Impact factor: 91.245
Authors: Thomas H Shin; Panyupa Pankhong; Jian Yan; Amir S Khan; Niranjan Y Sardesai; David B Weiner Journal: Hum Vaccin Immunother Date: 2012-02-16 Impact factor: 3.452
Authors: Mary C Bedard; Alessandro de Alarcon; Yann-Fuu Kou; David Lee; Alexandra Sestito; Angela L Duggins; Marion Brusadelli; Adam Lane; Kathryn A Wikenheiser-Brokamp; Susanne I Wells; David F Smith Journal: Cancers (Basel) Date: 2021-05-23 Impact factor: 6.639